Clinical Trial

Visually Guided TAP Block in Laparoscopic TAPP Hernia Repair

Study acronym: VIS-TAP-TAPP
Recruiting
View on ClinicalTrials.gov →
Summary
This prospective, randomized clinical study aims to evaluate the effectiveness of the Transversus Abdominis Plane (TAP) block performed under direct laparoscopic vision in reducing postoperative pain and improving recovery after laparoscopic inguinal hernia repair using the TAPP (Transabdominal Preperitoneal) technique. The study will enroll 100 adult patients undergoing elective laparoscopic TAPP hernia repair at the University Clinical Hospital in Olsztyn, Poland. Participants will be randomly assigned to two equal groups. In the study group, a bilateral TAP block will be performed under direct vision using 20 ml of 0.25% bupivacaine on each side after establishing pneumoperitoneum. The control group will undergo the same surgical procedure without the TAP block. All patients will receive standardized anesthesia and postoperative pain management according to hospital protocol. Postoperative pain intensity will be assessed using the Visual Analogue Scale (VAS) at 0, 6, and 12 hours after surgery. Additional data, such as time to mobilization, use of rescue analgesics, and occurrence of postoperative complications (hematoma, swelling, subcutaneous emphysema, transient muscle weakness), will also be recorded. The primary goal of this study is to determine whether a laparoscopically guided TAP block can effectively reduce postoperative pain and improve recovery parameters following TAPP hernia repair. The results may help establish a simple, safe, and reproducible method of multimodal analgesia in minimally invasive inguinal hernia surgery.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-23.
Status change: Not Yet Recruiting → Recruiting 2026-03-15
Trial Details
NCT Number NCT07264699
Lead Sponsor University of Warmia and Mazury in Olsztyn
Conditions Inguinal Hernia Repair, Postoperative Pain, TAP Block
Enrollment 100 participants
Start Date 2025-12-04
Primary Completion 2026-12 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-17